Inhaled mannitol improves lung function in cystic fibrosis.
about
Dornase alfa for cystic fibrosisInhaled mannitol for cystic fibrosisInhaled mannitol for cystic fibrosisThe Evolution of Cystic Fibrosis CareCystic fibrosis: exploiting its genetic basis in the hunt for new therapiesMeasuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapyNew horizons in the treatment of cystic fibrosis.Airway-rehydrating agents for the treatment of cystic fibrosis: past, present, and future.Evaluation of thiol-based antioxidant therapeutics in cystic fibrosis sputum: Focus on myeloperoxidase.Measurement of the airway surface liquid volume with simple light refraction microscopy.Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease.Hyper-osmolarity and calcium chelation: Effects on cystic fibrosis mucus.Liquid hyper-absorption as a cause of increased DTPA clearance in the cystic fibrosis airwayReduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.The cystic fibrosis intestine.Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis.Effect of apical hyperosmotic sodium challenge and amiloride on sodium transport in human bronchial epithelial cells from cystic fibrosis donors.Design, characterization, and aerosol dispersion performance modeling of advanced spray-dried microparticulate/nanoparticulate mannitol powders for targeted pulmonary delivery as dry powder inhalers.New and investigational treatments in cystic fibrosis.Challenges and advances in the development of inhalable drug formulations for cystic fibrosis lung disease.Bronchial provocation tests in clinical practice.Regulation of airway mucosal hydration.Inhaled mannitol for the treatment of cystic fibrosis.Mannitol dry powder for inhalation: in patients with cystic fibrosis.Effect of inhaled dry powder mannitol on mucus and its clearance.New pulmonary therapies directed at targets other than CFTR.Host mucin glycosylation plays a role in bacterial adhesion in lungs of individuals with cystic fibrosis.Improving complex medical care while awaiting next-generation CFTR potentiators and correctors: The current pipeline of therapeutics.New drug developments in the management of cystic fibrosis lung disease.The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers.Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence.Inhalation of tobramycin using simulated cystic fibrosis patient profiles.Quantitative functional characterization of conserved molecular interactions in the active site of mannitol 2-dehydrogenase.Hypertonic Saline Therapy in Cystic Fibrosis: Do Population Shifts Caused by the Osmotic Sensitivity of Infecting Bacteria Explain the Effectiveness of this Treatment?Hitting the target: new treatments for cystic fibrosis.Mannitol-guided delivery of Ciprofloxacin in artificial cystic fibrosis mucus model.Update in cystic fibrosis 2008.Bronchial provocation testing with dry powder mannitol in children with cystic fibrosis.Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study.Hypertonic saline in treatment of pulmonary disease in cystic fibrosis
P2860
Q24185927-7CE4B34E-10B5-413C-ABC7-D2A89CD36F0BQ24186558-44DBE34D-91B8-42FB-8BE1-62B26000DC41Q24236723-BA70FC7E-2E62-40AF-A357-ADDCAA91A492Q26999299-72732918-F78B-46A1-8057-E93BA0DEA5E1Q33664918-EA2176B9-9597-4ED2-9BD0-715A000D51B3Q33697276-4D7464FD-3DDC-4D6B-B320-2E296B30BA14Q33756002-DE3FF528-41F7-45C3-A736-1F4A67D410A1Q33771660-F62CCBD3-458E-4588-AD54-C3197371948BQ34479408-74BCF156-CFED-4ED4-9116-3B6CA64E6AB7Q35219853-EA03A12B-906C-43F4-8A81-6EDCE8FA8C89Q35801062-794C267A-3CF9-45E9-9C40-8479A9BCE9DDQ36144853-B5BDAA3A-990D-4082-9B56-D82D81D9FAD8Q36693624-9EF61B80-66DC-4BEE-ACCA-035665E04C05Q36999197-4F52CD4C-B36E-4801-BC2D-F0404E9D05E2Q37122355-D3173165-14C5-4F63-B283-22F1E5A9409AQ37158668-13F59E16-8861-41BB-9668-EEA4D60C36F6Q37439845-3E9C029A-9CF2-4343-B8E8-EE182160D05CQ37667617-987DC3A3-4F0A-4EF2-A49D-64559CD4518CQ37849458-4E9E0596-4C84-4128-BA47-BC143819FF08Q37849777-F69D0CAA-93D3-402D-8932-C25D3E6040BAQ37942490-C7579ACE-D75D-4A3E-8DC5-2A5A306A8034Q37960092-BE067D77-B4D7-4510-8C46-E5D8FB94DFA3Q37979246-2D82C6EC-946B-4D94-9B2F-3A5F1F516EC8Q38023470-61B0AA8E-7BD1-4663-B9EF-9336C5721F75Q38077798-6AD7930A-F360-4269-A856-DBDEA014E081Q38111645-EEE8CC1C-C154-4946-8A1C-6BD219C41A56Q38153821-9C124D2A-D998-44A2-BCC2-1A326EF5B603Q38579967-852AC05A-7004-43D8-A736-08F9AD2944B5Q38790382-27D2C502-F7D1-4233-B2AD-0FB890ABE0D3Q38980035-2F2DBB69-03F6-4D02-B335-2D0E1E763C1EQ39282311-C3906BBD-A88C-4078-8EA3-B999FE5794BFQ40505534-F1B67297-A9D4-470B-A7E4-649A26CD377FQ42113236-A6260D2A-D4E6-4EA9-9103-618A2B32181EQ42732058-2BF31DAB-379A-4A23-8030-170A5C3943F6Q42778357-FD8475B7-5950-4F48-8F2C-5008CF120274Q45082881-9C3AC964-3134-484A-87D4-B3E08DDF6187Q46098724-3FF93EB8-74AB-46AF-8141-1B98DD6C8F67Q46274587-E2E6FFA6-AE67-4B13-BE13-74A3B10A130BQ53139077-2E6E1DA7-DFD1-4722-AB7B-460B2A05469DQ58914917-73E8BA54-AEF2-41AA-B185-EBC63322DDD9
P2860
Inhaled mannitol improves lung function in cystic fibrosis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Inhaled mannitol improves lung function in cystic fibrosis.
@en
type
label
Inhaled mannitol improves lung function in cystic fibrosis.
@en
prefLabel
Inhaled mannitol improves lung function in cystic fibrosis.
@en
P2093
P356
P1433
P1476
Inhaled mannitol improves lung function in cystic fibrosis
@en
P2093
Anna Jaques
Brett Charlton
Bruce Shadbolt
Colin F Robertson
Evangelia Daviskas
James A Turton
Karen McKay
Peter Cooper
Peter T P Bye
Robert G Stirling
P304
P356
10.1378/CHEST.07-2294
P407
P577
2008-03-13T00:00:00Z